Aarti Drugs Ltd (AARTIDRUGS) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Aarti Drugs witnessed improved demand for Active Pharmaceutical Ingredients (APIs), leading to volume growth compared to Q1 FY25.
- API business grew by 5% year-on-year.
- Total revenues increased by 6% year-on-year to 591 crores.
- Gross profit margins improved by 130 basis points year-on-year due to input cost normalization.
- EBITDA increased by 12% year-on-year to 74 crores, with EBITDA margins improving to 12.6%.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.